uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13 2023 - 7:05AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that the Company granted equity awards to 31
employees as a material inducement to commencing their employment.
The equity awards were approved by the Company’s board of directors
on February 23, 2023 (the “Grant Date”) in accordance with Nasdaq
Listing Rule 5635(c)(4).
In the aggregate, the employees received 63,300
restricted share units (“RSUs”) and options to purchase 57,500
ordinary shares of the Company. Each option has an exercise price
of $20.06 per share, the closing price per ordinary share as
reported by Nasdaq on February 23, 2023. Each option has a ten-year
term and will vest over four years, with 25% of the original number
of shares vesting on the first anniversary of the Grant Date and an
additional 6.25% of the shares vesting in approximately equal
quarterly installments over the twelve successive quarters
thereafter. The RSUs will vest over three years, with one-third of
the RSUs vesting annually on each successive anniversary of the
Grant Date. The vesting of each option and RSU is subject to the
employee’s continued service with the Company through the
applicable vesting dates.
About uniQure
uniQure is delivering on the promise of gene
therapy – single treatments with potentially curative results. The
recent approvals of our gene therapy for hemophilia B – an historic
achievement based on more than a decade of research and clinical
development – represents a major milestone in the field of genomic
medicine and ushers in a new treatment approach for patients living
with hemophilia. We are now leveraging our modular and validated
technology platform to advance a pipeline of proprietary gene
therapies for the treatment of patients with Huntington's disease,
refractory temporal lobe epilepsy, ALS, Fabry disease, and other
severe diseases. www.uniQure.com
uniQure Contacts: |
|
|
|
FOR INVESTORS: |
FOR MEDIA: |
|
|
Chiara RussoDirect: 617-306-9137Mobile:
617-306-9137c.russo@uniQure.com |
Tom MaloneDirect: 339-970-7558Mobile:
339-223-8541t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024